Company intelligence / Profile preview

MLS

Melbourne, Victoria, Australia

Ownership: Private
Employees: ~3
Development stage: Other

Overview

MLS Bio has discovered a new cellular target and developed two small molecules: MLS-269 for cancer-agnostic applications (including advanced prostate cancer) and MLS-289 for broad-spectrum antiviral activity. Pre-IND FDA approvals obtained, with AU and US patents granted until 2041.[1][5]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MLS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MLS.

Explore the full profile